Earnings ·
Sionna Therapeutics reports $32.4M Q3 loss and cuts workforce by 46% to extend cash runway into 2029
SIONSionna Therapeutics, Inc.
Sionna Therapeutics reported a net loss of $32.4 million for the third quarter ended September 30, 2026, compared to a $20.3 million loss in the prior-year period. The company implemented a workforce reduction of approximately 46% and other cost-saving measures in September 2026 to focus resources on its SION-451 + SION-2222 dual combination program. Cash, cash equivalents, and marketable securities totaled $249.8 million as of September 30, 2026, which management expects will fund operations into the second half of 2029. The company plans to initiate a Phase 2 proof-of-concept trial for its lead combination in the first quarter of 2027. Sionna Therapeutics is a clinical-stage biopharmaceutical company developing novel medicines for cystic fibrosis.